Plasma phenylethylamine and phenylalanine in chronic schizophrenic patients.
The hypothesis that phenylethylamine (PEA) is an endogenous psychotogen in schizophrenics, particularly those with the paranoid subtype, has been previously studied by measuring PEA levels in urine and cerebrospinal fluid (CSF) of schizophrenic patients. However, plasma PEA may more accurately reflect simultaneous alterations of PEA in many organ systems, as might occur in a genetic disorder of PEA metabolism. No study to date has examined phenylalanine (Phe), which is thought to be a precursor of PEA, in the same patients who had PEA measured. In this study, we measure both plasma PEA and Phe in 17 drug-free schizophrenic patients and 17 matched controls. Plasma PEA in normal controls was found to be lower by three orders of magnitude compared to normal controls from previous studies--a finding that has not previously been reported. PEA was significantly lower in those schizophrenic patients who had a Research Diagnostic Criteria diagnosis of paranoid schizophrenia. PEA did not differ between patients and controls, and the correlation between plasma Phe and PEA was not significant.
D000328:Adult; D002908:Chronic Disease; D006801:Humans; D008875:Middle Aged; D010627:Phenethylamines / Q000097:blood*; D010649:Phenylalanine / Q000097:blood*; D012559:Schizophrenia / Q000097:blood*; D012563:Schizophrenia, Paranoid / Q000097:blood
D010627:Phenethylamines; C029261:phenethylamine; D010649:Phenylalanine